Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 154Observational 10Expanded_access 3

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1

Conditions

Solid Tumors 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Axitinib × Clear all
NCT05941637 2024-12-31

An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Lynkcell Europe

No longer available
Genitourinary

Kidney Neoplasms

NCT02354612 2021-02-15

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Tracon Pharmaceuticals Inc.

No longer available
Other solid neoplasm

Solid Tumors

NCT01473043 2014-05-30

Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

Pfizer

No longer available
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡